ERBB2 and breast cancer: IHC analysis of matched PT and metachronous brain metastatic lesions from seven HER2+ breast cancer patients revealed high expression of p-DRP1S616 in brain metastatic lesions compared to corresponding matched PTs (Fig. 5a,b).